Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02714569 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate LY3202328 in Overweight Healthy Participants and Dyslipidemia
A Phase 1 study of Dyslipidemias, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
- 4
- Study locations
NCT02714569 is a Phase 1 study of Dyslipidemias that has completed, run by Eli Lilly and Company. The registered enrollment target is 60 participants, below the 231-participant average among 28 other Dyslipidemias trials with a reported enrollment target (74% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT02714569, a Phase 1 study of Dyslipidemias, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
- 4
- Study locations
Study Summary
The purpose of this two-part study is to evaluate the safety and tolerability of the study drug known as LY3202328 in healthy overweight participants in Part A, and those with dyslipidemia (abnormal blood fats) in Part B.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Simvastatin
- DRUG Atorvastatin
- DRUG LY3202328
Study Locations (4)
Florida
- Clinical Pharmacology of Miami, Inc. - Miami
Kansas
- PRA Health Sciences - Lenexa
New Jersey
- PRA Health Sciences - Marlton
Utah
- PRA Health Sciences - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2016-03 |
| Est. Completion | 2017-02-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02714569
The ClinicalTrials.gov registry entry for NCT02714569 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 231-participant average among 28 other Dyslipidemias trials with a reported enrollment target (74% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Dyslipidemias appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT02714569 reports 4 study locations spanning 4 distinct geographic areas - top geographies include Florida, Kansas, New Jersey.
Frequently Asked Questions
What is clinical trial NCT02714569 about?
NCT02714569 is a clinical study titled "A Study to Evaluate LY3202328 in Overweight Healthy Participants and Dyslipidemia". The purpose of this two-part study is to evaluate the safety and tolerability of the study drug known as LY3202328 in healthy overweight participants in Part A, and those with dyslipidemia (abnormal blood fats) in Part B.
What is the current status of trial NCT02714569?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2016-03. Estimated completion is 2017-02-15.
What conditions does trial NCT02714569 study?
This clinical trial studies the following conditions: Dyslipidemias.
What interventions are being tested in trial NCT02714569?
The interventions under investigation include: Placebo (DRUG), Simvastatin (DRUG), Atorvastatin (DRUG), LY3202328 (DRUG).
Who is sponsoring clinical trial NCT02714569?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02714569 being conducted?
This trial has 4 study locations across Florida, Kansas, New Jersey, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Dyslipidemias
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Investigate Safety, Tolerability, PK and PD Response of SLN360 in Subjects With Elevated Lipoprotein(a)
COMPLETED · Phase 1
-
A Study of LY3475766 in Healthy Participants
COMPLETED · Phase 1
-
Dose Response Effects of Pecan Consumption
RECRUITING · NA
-
Cottonseed Oil Dose Response
RECRUITING · NA
-
'Ai Pono Cooking Demonstrations
RECRUITING · NA
-
Randomized Controlled Trial of Alert-Based Computerized Decision Support for Patients With Peripheral Artery Disease Not Prescribed Lipid-Lowering Therapy
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.